Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Clinical trial NCT00523848 · COMPLETED

Trial details

NCT number

NCT00523848

Sponsor

Roswell Park Cancer Institute

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2006-06-01

Primary completion

2011-09-01

Enrollment

46

View on ClinicalTrials.gov